New insider activity at Iradimed ( (IRMD) ) has taken place on December 10, 2025.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Director James Hawkins recently sold 3,000 shares of Iradimed stock, generating a total of $289,830 from the transaction.
Recent Updates on IRMD stock
Iradimed Corporation’s stock has seen recent positive developments, primarily driven by the company’s strong financial performance and strategic decisions. The Board of Directors declared a special cash dividend of $0.50 per share, reflecting robust financial health with 17 consecutive quarters of record revenue and a substantial cash balance. This move underscores the company’s commitment to maximizing shareholder returns. Analysts have raised the stock’s price target, citing record growth and optimism from recent earnings calls, as well as positive technical analysis trends. However, they also note potential risks such as regulatory challenges and high operating expenses.
Spark’s Take on IRMD Stock
According to Spark, TipRanks’ AI Analyst, IRMD is a Outperform.
Iradimed’s overall stock score is driven by strong financial performance and positive earnings call sentiment, indicating robust growth prospects. However, technical indicators suggest potential short-term volatility, and the high P/E ratio raises valuation concerns. The special dividend announcement further supports shareholder value.
To see Spark’s full report on IRMD stock, click here.
More about Iradimed
YTD Price Performance: 77.80%
Average Trading Volume: 68,503
Technical Sentiment Signal: Buy
Current Market Cap: $1.21B